Message from the CEO
At Infinity, our goal is to deliver revolutionary treatments to patients that can make a meaningful difference in their lives.
We have spent the past few years focused on advancing a diverse portfolio of innovative products, building an exceptional team and maintaining a very strong financial position. With three product candidates in the clinic, we are now reaching a place where our goal is in sight.
In building our pipeline, we have intentionally pursued targets with applicability across multiple therapeutic areas and indications. This approach gives us several product opportunities in areas with broad commercial potential. This strategy also ensures that our success is not dependent on any single product or indication, allowing us to optimize our portfolio on several dimensions in response to new data. We’ve made important progress with our portfolio over the last past year. With six clinical trials underway across three programs, we expect to report data in 2012 that will inform the potential paths to registration for four out of these six studies.
We partner with some of the best pharmaceutical and biotechnology companies, enabling us to develop more product candidates than we could advance on our own while maintaining a strong financial foundation. For example, our strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. provides us with R&D funding and gives us access to markets outside the U.S.
The progress we have made – and that we will continue to make – is made possible by the talented and passionate Citizen-Owners at Infinity. We have a shared commitment to collaboration and innovation, as well as scientific and business excellence. We are excited about the progress we are making in delivering meaningful therapies to patients, and we will remain disciplined in building for, and investing in, sustainable future success.
We welcome your interest in our company.
Sincerely,
Adelene Q. Perkins
President and Chief Executive Officer